Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Common Equity (2009 - 2025)

Grifols' (GIFLF) quarterly Common Equity came in at $6.1 billion in Q4 2025, down 2.4% on a YoY basis from $6.3 billion in Q4 2024, and down 2.4% quarter-over-quarter from $6.3 billion in Q4 2024.

Analysis

Grifols (GIFLF) Common Equity (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Common Equity for 17 consecutive years, with $6.1 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 2.4% year-over-year to $6.1 billion; the trailing twelve-month figure through Dec 2025 stood at $6.1 billion (down 2.4% YoY), and the FY2025 full-year result was $6.0 billion, up 21368.7% from the prior year.
  • Common Equity retreated to $6.1 billion in Q4 2025 per GIFLF's latest filing, from $6.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $8.1 billion in Q4 2022 and bottomed at $6.1 billion in Q4 2025.
  • Historically, Common Equity has averaged $7.3 billion across 5 years, with a median of $7.8 billion in 2021.
  • The sharpest annual moves came in 2022 and 2024: Common Equity rose 3.73% in 2022, then fell 22.23% in 2024.
  • Over 5 years, Common Equity stood at $7.8 billion in 2021, then increased by 3.73% to $8.1 billion in 2022, then dropped by 0.68% to $8.1 billion in 2023, then decreased by 22.23% to $6.3 billion in 2024, then dropped by 2.4% to $6.1 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods registered $6.1 billion, $6.3 billion, and $8.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 8.42 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 1.35 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 4.92 Bn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 6.14 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 6.14 Bn
Dec 31, 2024 6.29 Bn
Dec 31, 2023 8.08 Bn
Dec 31, 2022 8.14 Bn
Dec 31, 2021 7.85 Bn
Dec 31, 2020 8.01 Bn
Sep 30, 2020 8.30 Bn
Mar 31, 2020 7.96 Bn
Dec 31, 2019 7.58 Bn
Sep 30, 2019 5.89 Bn
Dec 31, 2018 5.36 Bn
Sep 30, 2018 4.82 Bn
Jun 30, 2018 4.73 Bn
Mar 31, 2018 5.99 Bn
Dec 31, 2017 4.28 Bn
Jun 30, 2017 3.94 Bn
Dec 31, 2016 4.02 Bn
Sep 30, 2016 3.94 Bn
Jun 30, 2016 3.85 Bn
Mar 31, 2016 3.64 Bn